Showing 2351-2360 of 5623 results for "".
- Stoke Therapeutics Presents New In-Vivo Data Demonstrating Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002https://modernod.com/news/stoke-therapeutics-presents-new-in-vivo-data-demonstrating-dose-related-target-engagement-and-opa1-protein-upregulation-in-retinal-tissue-following-administration-of-stk-002/2480831/Stoke Therapeutics announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein increases were sus
- Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-detailed-18-month-results-from-phase-3-derby-and-oaks-studies-of-pegcetacoplan-for-geographic-atrophy-ga-at-arvo/2480830/Apellis Pharmaceuticals announced detailed, longer-term data from the phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Monthly and
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these
- SightGlass Vision Presents 24-Month Data Demonstrating Myopia Control Efficacy for Vision Spectacle Lenseshttps://modernod.com/news/sightglass-vision-presents-24-month-data-demonstrating-myopia-control-efficacy-for-vision-spectacle-lenses/2480823/Spectacles that use SightGlass Vision Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children,[1] based on 24-month interim data from its pivotal c
- Schwind Celebrates 30 Years in Refractive Corneal Surgeryhttps://modernod.com/news/schwind-celebrates-30-years-in-refractive-corneal-surgery/2480804/In 2022, Schwind eye-tech-solutions is celebrating a milestone, as the company marks 30 years of driving solutions for refractive corneal surgery. During this period, Schwind has expanded its treatment options for eye surgeons and patients. Founded in 1958 and initially a successful one-stop supp
- Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022https://modernod.com/news/tarsus-presents-results-of-two-studies-highlighting-demodex-blepharitis-patient-impact-and-burden-at-the-ascrs-2022-annual-meeting/2480803/Tarsus Pharmaceuticals presented data from its Atlas Continuation study on the negative impacts to daily life and visual function, and preliminary findings from its Pandora study on pathogenic bacterial count, for patients with Demodex blepharitis at the American S
- CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgerieshttps://modernod.com/news/corneagen-advances-next-generation-of-dsek-surgery-innovation/2480789/CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries. “We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- Zeiss Announces FDA Clearance of the Quatera 700 Phaco Devicehttps://modernod.com/news/zeiss-announces-fda-clearance-of-the-quatera-700-phaco-technology/2480779/Zeiss announced that the FDA has cleared the Quatera 700, which includes the Zeiss patented Quattro Pump designed to deliver chamber stability independent of IOP and flow. “What excites me the most about the Quatera 700 is the Quattro pump’
- Nova Eye Medical Launches Next Generation Canaloplasty Device for Glaucoma, iTrack Advancehttps://modernod.com/news/nova-eye-medical-launches-next-generation-canaloplasty-device-for-glaucoma-itrack-advance/2480774/Nova Eye Medical announced the launch of its next generation canaloplasty device, iTrack Advance, in select markets in Europe and the Asia Pacific. The iTrack Advance features the proprietary illuminated fiber optic tip of the original iTrack device, which all